Evolyra Therapeutics

Seed
evolyratherapeutics.com Biotech & Healthcare University Of Richmond, United States
Total Funding Undisclosed
Latest Round Undisclosed Seed
Last Announced Apr 1, 2026
Investors Undisclosed
Decision Makers 1 Verified

About Evolyra Therapeutics

Evolyra Therapeutics develops next-generation AAV gene therapies for limb-girdle muscular dystrophy and other rare neuromuscular diseases.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Seed
Global Headquarters University Of Richmond, United States
Tracked Since Oct 2, 2026

Web & Domain Identity

Official Website evolyratherapeutics.com
Domain Registered Date Aug 6, 2025

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Seed announced

  2. Milestone

    Website domain registered

    evolyratherapeutics.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Evolyra Therapeutics.

Funding History

1 Round
Seed equity · Apr 1, 2026
Undisclosed

Founders & Leadership

4

Ellie Carrell

Founder

Work email & phone locked Unlock →

Kevin Passarello

Founder

Work email & phone locked Unlock →

Melissa Hale

Founder

Work email & phone locked Unlock →

Nicholas Johnson

Founder

Work email & phone locked Unlock →

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts